Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Advances analyze found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://brettu107lew8.aboutyoublog.com/profile